

Mipomersen sodium

Cat. No.:	HY-108764
CAS No.:	629167-92-6
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Mipomersen (sodium)

BIOLOGICAL ACTIVITY

Description	Mipomersen (sodium) is a second-generation 20-base phosphorothioate ASO targeted to human apoB-100 ^{[1][2]} .
In Vitro	<p>Mipomersen predominantly distributes to the liver and decreases the production of apoB-100, the primary structural protein of the atherogenic lipoproteins including low density lipoprotein (LDL), thereby reducing plasma LDL-cholesterol and apoB-100 concentrations^[2].</p> <p>Apolipoprotein (apo) B, a large amphipathic protein, plays a fundamental role in human lipoprotein metabolism. ApoB-100 is also a ligand for LDL receptor-mediated endocytosis of LDL by cells^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Philip Hair, et al. Mipomersen sodium: first global approval. *Drugs*. 2013 Apr;73(5):487-93.
- [2]. Damon A Bell, et al. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. *Expert Opin Investig Drugs*. 2011 Feb;20(2):265-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA